- Health Care Service Corp. said to eye Cigna Medicare Advantage
- Potential Cigna-Humana tie-up likely to face antitrust concern
In recent months, Cigna has been taking steps to get around that hurdle by shopping its relatively smaller Medicare Advantage business, a move that made little sense on its own before news broke of the Cigna-Humana talks.
That business has drawn interest from potential buyers including
Representatives for HCSC and Cigna declined to comment.
A sale of Cigna’s Medicare Advantage business would remove one obstacle to a
After falling 8.1% Wednesday, Cigna shares rose 0.6% before US markets opened Thursday. Humana’s, which lost 5.5% Wednesday, gained 1% early Thursday.
Talk of Cigna selling its Medicare Advantage business broke with a Reuters report in early November. On its own, the move seemed to contradict the company’s long-term vision. Cigna has told investors that Medicare will be an important source of its growth for years to come.
The Connecticut-based insurer is a relatively minor player in that business, with fewer than 600,000 Medicare Advantage enrollees as of March, according to data from health researcher KFF. Humana, meanwhile, is the second-largest, with more than 5 million members, and its business is largely focused on Medicare.
Humana decided this year to
Even with those changes, a combination between Cigna and Humana would face regulatory hurdles. Cigna’s Express Scripts unit is the second-largest pharmacy benefits manager with about a quarter of the market, while Humana is the fourth largest, according to the Drug Channels Institute.
Both companies already
(Updates with premarket shares in sixth paragraph.)
To contact the reporters on this story:
To contact the editors responsible for this story:
Michael Hytha, John Lauerman
© 2023 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.